CTI BioPharma Corp. (CTIC)

$5.44

+0.15 (+2.84%)
Rating:
Recommendation:
Neutral
Symbol CTIC
Price $5.44
Beta 0.986
Volume Avg. 6.40M
Market Cap 592.780M
Shares () -
52 Week Range 1.43-5.76
1y Target Est -
DCF Unlevered CTIC DCF ->
DCF Levered CTIC LDCF ->
ROE -616.49% Strong Sell
ROA -89.64% Strong Sell
Operating Margin -
Debt / Equity -570.81% Strong Sell
P/E -
P/B -19.45 Strong Sell
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CTIC news


Dr. Adam R. Craig
Healthcare
Biotechnology
NASDAQ Capital Market

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.